HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KNSA
Kiniksa Pharmaceuticals, Ltd.
KNSA's fundamentals are strong: revenue grew 58% and its operating margin rose 7 points to 14%. At 74x earnings, it's trading in line with its usual 69x. Analysts expect that strong growth to continue, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KNSA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
KNSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KNSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.2x | $6.87 | -93% |
| Forward | 63x | $96.28 | — |
| Fair | 67x | $87.85 | -8.8% |
| Current | 74x | $96.28 | — |
| Expensive | 143x | $188 | +95% |
Historical ranges are pointers, not guarantees.
KNSA's PE is in its fair range at 74x. If earnings grow as analysts expect, today's price would be 63x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KNSA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for KNSA, but weaker profitability. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
KNSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +16% |
| Q3 2026 | $1.31 | +185% |
| Q2 2026 | $0.98 | +1860% |
| Q1 2026 | $0.91 | +$1.15 |
| Q4 2025 | $0.75 | +$1.35 |
| Q3 2025 | $0.46 | +$0.58 |
| Q2 2025 | $0.05 | +$0.19 |
| Q1 2025 | -$0.24 | -285% |
| Q4 2024 | -$0.60 | -400% |
KNSA has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KNSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $286M | +58% |
| Q2 2026 | $243.6M | +55% |
| Q1 2026 | $214.3M | +56% |
| Q4 2025 | $202.1M | +65% |
| Q3 2025 | $180.9M | +61% |
| Q2 2025 | $156.8M | +44% |
| Q1 2025 | $137.8M | +73% |
| Q4 2024 | $122.5M | +47% |
KNSA has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +5.7 points |
| Q2 2026 | 11% | -1.7 points |
| Q1 2026 | 14% | +4 points |
| Q4 2025 | 9.8% | +26 points |
| Q3 2025 | 13% | +22 points |
| Q2 2025 | 13% | +13 points |
| Q1 2025 | 9.6% | +30 points |
| Q4 2024 | -16% | -16 points |
KNSA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
KNSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.4M | +44% |
| Q2 2026 | $46.5M | +67% |
| Q1 2026 | $50M | +125% |
| Q4 2025 | $53.3M | +187% |
| Q3 2025 | $33M | +$35.2M |
| Q2 2025 | $27.9M | +440% |
| Q1 2025 | $22.2M | +469% |
| Q4 2024 | $18.6M | +335% |
KNSA has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KNSA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KNSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +1.5M shares |
| 1 year | +6.1% | +4.9M shares |
| 3 years | +21% | +14.7M shares |
| 5 years | +24% | +16.3M shares |
| Available history | +57% | +30.9M shares |
KNSA has 85M diluted shares, up 6.1% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KNSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -4.4x | Net Cash |
| Q2 2025 | -32.1x | Net Cash |
| Q2 2023 | -2.8x | Net Cash |
| Q1 2023 | -3.3x | Net Cash |
KNSA has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KNSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.8 | Overbought |
| Stochastic | 85.1 | Overbought |
KNSA's weekly RSI is 80 (overbought) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KNSA PE vs Healthcare Sector
| Metric | KNSA | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 184% above |
| PE % | 54 | 29 | 25 pts above |
KNSA is trading at 74x earnings, a 184% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KNSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $83.5 | 15% above |
| 20 week MA | $76.9 | 25% above |
| 50 week MA | $59.0 | 63% above |
| 100 week MA | $43.7 | 121% above |
| 200 week MA | $30.9 | 211% above |
KNSA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
KNSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.7 | $19.0 | +62% |
| 2021 | $19.0 | $13.1 | -31% |
| 2022 | $13.1 | $15.5 | +18% |
| 2023 | $15.5 | $17.5 | +13% |
| 2024 | $17.5 | $20.0 | +14% |
| 2025 | $20.0 | $42.0 | +110% |
| 2026 YTD | $42.0 | $96.3 | +129% |
KNSA has the edge over HIMS on returns for 2026, with the stronger performance.